Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib

BACKGROUND. A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients. The primary endpoint of progression-free survival (PFS) in patients whose tumors were human epiderma...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sherrill, Beth, Amonkar, Mayur M., Sherif, Bintu, Maltzman, Julie, O'Rourke, Lisa, Johnston, Stephen
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2010
Teme:
Academia–Pharma Intersect
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228031/
https://ncbi.nlm.nih.gov/pubmed/20798196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0012
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items